Effects of the Insulin-Sensitizing Drug Pioglitazone and Lipopolysaccharide Administration on Insulin Sensitivity in Horses

Journal of Veterinary Internal Medicine

Volumn 25, Issue 2, 2011, Pages 356-364

  Suagee, J K ^a   Corl, B A ^a   Wearn, J G ^b   Crisman, M V ^b   Hulver, M W ^a   Geor, R J ^a,c   Mccutcheon, L J ^b,c  

^a VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^b VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

^c MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

GLUT4; Insulin receptor; Skeletal muscle; Subcutaneous adipose tissue

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; INSULIN; LIPOPOLYSACCHARIDE; PIOGLITAZONE;

ADIPOSE TISSUE; ANIMAL; ARTICLE; FEMALE; GLUCOSE BLOOD LEVEL; HORSE; HORSE DISEASE; INSULIN RESISTANCE; METABOLISM; RANDOMIZATION; SKELETAL MUSCLE; TREATMENT OUTCOME;

ADIPOSE TISSUE; ANIMALS; BLOOD GLUCOSE; FEMALE; HORSE DISEASES; HORSES; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; LIPOPOLYSACCHARIDES; MUSCLE, SKELETAL; RANDOM ALLOCATION; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

ANIMALIA; EQUIDAE;

EID: 79952322814     PISSN: 08916640     EISSN: 19391676     Source Type: Journal    
DOI: 10.1111/j.1939-1676.2011.0681.x     Document Type: Article

References (35)

1. Kahn CR. Insulin resistance, insulin insensitivity, and insulin unresponsiveness: A necessary distinction. Metabolism 1978;12:1893-1902.
2. Jeffcott LB, Field JR, McLean JG, et al. Glucose tolerance and insulin sensitivity in ponies and Standardbred horses. Equine Vet J 1986;18:97-101.
3. Carter R, Treiber KH, Geor RJ, et al. Prediction of incipient pasture-associated laminitis from hyperinsulinaemia, hyperleptinaemia and generalised and localised obesity in a cohort of ponies. Equine Vet J 2009;41:171-178.
4. Vick MM, Adams AA, Murphy BA, et al. Relationships among inflammatory cytokines, obesity, and insulin sensitivity in the horse. J Anim Sci 2007;85:1144-1155.
5. Hauner H, Petruschke TH, Russ M, et al. Effects of tumor necrosis factor alpha (TNFα) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia 1995;38:764-771.
6. Hustace JL, Firshman AM, Mata JE. Pharmacokinetics and bioavailability of metformin in horses. Am J Vet Res 2009;70:665-668.
7. Weyenberg SV, Hesta M, Buyse J, et al. The effect of weight loss by energy restriction on metabolic profile and glucose tolerance in ponies. J Anim Physiol Anim Nutr 2008;92:538-545.
8. Ding S, Shen Z, Chen Y, et al. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats. Acta Pharmacol Sin 2005;26:575-580.
9. Hammarstedt A, Rotter Sopasakis V, Gogg S, et al. Improved insulin sensitivity and adipose tissue dysregulation after short-term treatment with pioglitazone in non-diabetic, insulin-resistant subjects. Diabetologia 2005;48:96-104.
10. Wearn JMG, Crisman MV, Davis JL, et al. Pharmacokinetics of pioglitazone in horses after oral administration. J Vet Pharmacol Therap DOI: DOI: 10.1111/j.0140-7783.2010.01217.x.
11. Kletzien RF, Clarke SD, Ulrich RG. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 1992;41:393-398.
12. Chawla A, Barak Y, Nagy L, et al. PPARγ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 2001;7:48-52.
13. Gurnell M. Peroxisome proliferator-activated receptor γ and the regulation of adipocyte function: Lessons from human genetic studies. Best Prac Res Clin Endocrinol Metab 2005;19:501-523.
14. Vick MM, Murphy BA, Sessions DR, et al. Effects of systemic inflammation on insulin sensitivity in horses and inflammatory cytokine expression in adipose tissue. Am J Vet Res 2008;69:130-139.
15. Henneke DR, Potter GD, Kreider JL, et al. Relationship between condition score, physical measurements and body fat percentage in mares. Equine Vet J 1983;15:371-372.
16. Carter RA, McCutcheon LJ, George LA, et al. Effects of diet-induced weight gain on insulin sensitivity and plasma hormone and lipid concentrations in horses. Am J Vet Res 2009;70:1250-1258.
17. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008;3:1101-1108.
18. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of Type 2 diabetes mellitus: Peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004;89:463-478.
19. Eckland D, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol Diabetes 2000;108:S234-S242.
20. Toth F, Frank N, Elliott SB, et al. Effects of an intravenous endotoxin challenge on glucose and insulin dynamics in horses. Am J Vet Res 2008;69:82-88.
21. Shadid S, Jensen M. Pioglitazone increases non-esterified fatty acid clearance in upper body obesity. Diabetologia 2006;49:149-157.
22. McLaughlin TM, Liu T, Yee G, et al. Pioglitazone increases the proportion of small cells in human abdominal subcutaneous adipose tissue. Obesity 2009;18:926-931.
23. Ranganathan G, Unal R, Pokrovskaya I, et al. The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue: Effects of obesity, insulin resistance, and TZD treatment. J Lipid Res 2006;47:2444-2450.
24. Bogacka I, Xie H, Bray GA, et al. The effect of pioglitazone on peroxisome proliferator-activated receptor-γ target genes related to lipid storage in vivo. Diabet Care 2004;27:1660-1667.
25. Sandouk T, Reda D, Hofmann C. The antidiabetic agent pioglitazone increases expression of glucose transporters in 3T3-F442A cells by increasing messenger ribonucleic acid transcript stability. Endocrinology 1993;133:352-359.
26. Frank N, Elliott SB, Brandt LE, et al. Physical characteristics, blood hormone concentrations, and plasma lipid concentrations in obese horses with insulin resistance. J Am Vet Med Assoc 2006;228:1383-1390.
27. DeFronzo RA. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidaemia and atherosclerosis. Neth J Med 1997;50:191-197.
28. Hayakawa T, Shiraki T, Morimoto T, et al. Pioglitazone improves insulin signaling defects in skeletal muscle from Wistar fatty (fa/fa) rats. Biochem Biophys Res Comm 1996;223:439-444.
29. Frohnert BI, Hui TY, Bernlohr DA. Identification of a functional peroxisome proliferator-responsive element in the murine fatty acid transport protein gene. J Biol Chem 1999;274:3970-3977.
30. Kolak M, Yki-Jarvinen H, Kannisto K, et al. Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J Clin Endocrinol Metab 2007;92:720-724.
31. Todd MK, Watt MJ, Le J, et al. Thiazolidinediones enhance skeletal muscle triacylglycerol synthesis while protecting against fatty acid-induced inflammation and insulin resistance. Am J Phys Endocrinol Metab 2007;292:E485-493.
32. Szalkowski D, White-Carrington S, Berger J, et al. Antidiabetic thiazolidinediones block the inhibitory effect of tumor necrosis factor-alpha on differentiation, insulin-stimulated glucose uptake, and gene expression in 3T3-L1 cells. Endocrinology 1995;136:1474-1481.
33. Krogh-Madsen R, Plomgaard P, Akerstrom T, et al. Effect of short-term intralipid infusion on the immune response during low-dose endotoxemia in humans. Am J Physiol Endocrinol Metab 2008;294:E371-379.
34. Zu L, He J, Jiang H, et al. Bacterial endotoxin stimulates adipose lipolysis via toll-like receptor 4 and extracellular signal-regulated kinase pathway. J Biol Chem 2009;284:5915-5926.
35. Maitra U, Chang S, Singh N, et al. Molecular mechanism underlying the suppression of lipid oxidation during endotoxemia. Mol Immunol 2009;47:420-425.